Drug Profile
Research programme: antibody-drug conjugate therapeutics - Synaffix
Latest Information Update: 23 Oct 2022
Price :
$50
*
At a glance
- Originator Synaffix
- Developer Synaffix; Unknown
- Class Antibodies; Antineoplastics; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer